Ken Fisher’s AZN Holdings & Trades

First Buy
Q3 2015
Duration Held
41 Quarters
Largest Add
Q1 2025
+9.21 M Shares
Current Position
21.16 M Shares
$1.62 B Value

Ken Fisher's AZN Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 21.16 M shares of AstraZeneca PLC (AZN) worth $1.62 B, representing 0.59% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.

Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in AZN, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 9.21 M shares. Largest reduction occurred in Q3 2022, reducing 12.44 M shares.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's AstraZeneca PLC (AZN) Holding Value Over Time

Track share changes against reported price movement

Quarterly AstraZeneca PLC (AZN) Trades by Ken Fisher

Period Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2015 +27,947 New Buy 27,947 $31.81
Q4 2015 +193,659 Add 692.95% 221,606 $33.95
Q1 2016 +11,803 Add 5.33% 233,409 $29.71
Q2 2016 +105,570 Add 45.23% 338,979 $29.97
Q3 2016 +1.64 M Add 483.39% 1.98 M $32.86
Q4 2016 -26,586 Reduce 1.34% 1.95 M $27.32
Q1 2017 -29,907 Reduce 1.53% 1.92 M $31.14
Q2 2017 +9.16 M Add 476.85% 11.08 M $34.09
Q3 2017 +519,717 Add 4.69% 11.6 M $33.88
Q4 2017 +315,759 Add 2.72% 11.92 M $34.70
Q1 2018 +626,827 Add 5.26% 12.54 M $34.97
Q2 2018 +535,782 Add 4.27% 13.08 M $35.11
Q3 2018 +436,783 Add 3.34% 13.52 M $39.57
Q4 2018 +1.45 M Add 10.72% 14.97 M $37.98
Q1 2019 +409,357 Add 2.74% 15.37 M $40.43
Q2 2019 +529,694 Add 3.45% 15.9 M $41.28
Q3 2019 +357,670 Add 2.25% 16.26 M $44.57
Q4 2019 +108,747 Add 0.67% 16.37 M $49.86
Q1 2020 +185,866 Add 1.14% 16.56 M $44.66
Q2 2020 +370,371 Add 2.24% 16.93 M $52.89
Q3 2020 +415,735 Add 2.46% 17.34 M $54.80
Q4 2020 +508,094 Add 2.93% 17.85 M $49.99
Q1 2021 +537,914 Add 3.01% 18.39 M $49.72
Q2 2021 +441,805 Add 2.40% 18.83 M $59.90
Q3 2021 +759,134 Add 4.03% 19.59 M $60.06
Q4 2021 +520,259 Add 2.66% 20.11 M $58.25
Q1 2022 +732,959 Add 3.64% 20.84 M $66.34
Q2 2022 +544,887 Add 2.61% 21.39 M $66.07
Q3 2022 -12.44 M Reduce 58.19% 8.94 M $54.84
Q4 2022 -240,500 Reduce 2.69% 8.7 M $67.80
Q1 2023 +47,644 Add 0.55% 8.75 M $69.41
Q2 2023 +181,126 Add 2.07% 8.93 M $71.57
Q3 2023 +239,817 Add 2.69% 9.17 M $67.72
Q4 2023 +205,185 Add 2.24% 9.38 M $67.35
Q1 2024 +277,218 Add 2.96% 9.65 M $67.75
Q2 2024 +302,574 Add 3.13% 9.96 M $77.99
Q3 2024 +524,175 Add 5.26% 10.48 M $77.91
Q4 2024 +479,692 Add 4.58% 10.96 M $65.52
Q1 2025 +9.21 M Add 83.99% 20.17 M $73.50
Q2 2025 +530,520 Add 2.63% 20.7 M $69.88
Q3 2025 +466,745 Add 2.26% 21.16 M $76.72

Ken Fisher's AstraZeneca PLC Investment FAQs

Ken Fisher first purchased AstraZeneca PLC (AZN) in Q3 2015, acquiring 27,947 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held AstraZeneca PLC (AZN) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher's largest addition to AstraZeneca PLC (AZN) was in Q1 2025, adding 20,165,459 shares worth $1.48 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 21,162,724 shares of AstraZeneca PLC (AZN), valued at approximately $1.62 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

As of the Q3 2025 filing, AstraZeneca PLC (AZN) represents approximately 0.59% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher's peak holding in AstraZeneca PLC (AZN) was 21,387,732 shares, as reported at the end of Q2 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.